Octreotide Ratiopharm (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreotide Ratiopharm, is a somatostatin analog presented as a sterile solution for subcutaneous injection use. It controls hormone‑related symptoms and tumor growth in patients with neuroendocrine tumours and related endocrine disorders. GNH USA supplies Octreotide Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

GNH USA supplies Octreotide Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Octreotide Ratiopharm is a somatostatin analogue that modulates hormone secretion in several endocrine‑related conditions.

- Acromegaly: reduces excessive growth‑hormone secretion and associated tissue overgrowth. - Neuroendocrine tumours: controls hormone‑related flushing and diarrhoea, and can inhibit tumour proliferation. - Carcinoid syndrome: lessens flushing, wheezing and diarrhoea associated with serotonin excess. - Severe hypoglycaemia: raises blood glucose by inhibiting insulin release. - Post‑operative post‑pancreatic surgery complications : helps manage persistent vom  g